GRAIL Future Growth

Future criteria checks 1/6

GRAIL is forecast to grow earnings and revenue by 35.7% and 17.9% per annum respectively while EPS is expected to grow by 50.8% per annum.

Key information

35.7%

Earnings growth rate

50.8%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate17.9%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:NL0 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026169-588-402-3941
12/31/2025138-663-464-4562
12/31/2024120-2,107-649-6412
9/30/2024118-2,117-621-613N/A
6/30/2024110-2,883-676-665N/A
3/31/2024100-1,491-645-633N/A
12/31/202393-1,466-609-596N/A
1/1/202356-5,399-584-561N/A
1/2/202215-1,248-758-688N/A
6/30/20211-387-363-295N/A
3/31/20210-350-303-263N/A
12/31/2020N/A-312-244-232N/A
9/30/2020N/A-284-215-212N/A
6/30/2020N/A-264-215-213N/A
3/31/2020N/A-254-232-229N/A
12/31/2019N/A-245-249-246N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NL0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NL0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NL0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NL0's revenue (17.9% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: NL0's revenue (17.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NL0's Return on Equity is forecast to be high in 3 years time


Discover growth companies